Skip to main content
SMS Pharmaceuticals Ltd logo

SMS Pharmaceuticals Ltd — Investor Relations & Filings

Ticker · SMSPHARMA ISIN · INE812G01025 LEI · 335800XXEADQCB7GJ514 BSE.NS Manufacturing
Open in API
Filings indexed 747 across all filing types
Latest filing 2021-08-09 Regulatory Filings
Country IN India
Listing BSE.NS SMSPHARMA

About SMS Pharmaceuticals Ltd

https://smspharma.com/

SMS Pharmaceuticals Ltd specializes in the development and large-scale manufacturing of Active Pharmaceutical Ingredients (APIs) and advanced intermediates. The organization operates multiple manufacturing units and research centers, maintaining compliance with international regulatory standards including USFDA approvals. Its core product portfolio covers therapeutic areas such as anti-ulcerants, anti-migraine agents, anti-hypertensives, and anti-retrovirals. Beyond its proprietary product line, the company provides Contract Research and Manufacturing Services (CRAMS), offering expertise in process development, chemical synthesis, and analytical validation. The company focuses on delivering high-quality chemical solutions through integrated research and development capabilities, supporting global supply chains with a commitment to technical excellence and operational efficiency.

Recent filings

Filing Released Lang Actions
Press Release
Regulatory Filings
2021-08-09 English
Copy of Newspaper Publication
Regulatory Filings
2021-08-09 English
Updates
Regulatory Filings
2021-08-07 English
Updates
Major Shareholding Notification Classification · 95% confidence The document contains a table listing names, number of shares, and percentage ownership, indicating a notification of shareholdings. There is no indication of a full report, financial data, or regulatory announcements beyond share ownership. The document length is very short (331 characters), and it specifically lists shareholding percentages, which aligns with a Major Shareholding Notification.
2021-08-07 English
Outcome of Board Meeting
Regulatory Filings
2021-08-07 English
Financial Result Updates
Interim / Quarterly Report Classification · 95% confidence The document contains detailed standalone and consolidated unaudited financial results for the quarter ended June 30, 2021, including comprehensive financial data such as revenue, expenses, profit before tax, tax expenses, net profit, and earnings per share. It also includes notes on the review and approval of these financial results by the Audit Committee and Board of Directors, and mentions a limited review report by statutory auditors. The document also discusses reclassification of promoter shareholding and dividend distribution policy, but the primary content is the quarterly financial results with substantive financial data and analysis. This fits the definition of an Interim / Quarterly Report (IR). The document is about 15,000 characters, indicating it is a full report rather than a brief announcement or certification. Therefore, the correct classification is IR with high confidence.
2021-08-07 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.